Key Notes
- Nick Bostrom argues that safely developed superintelligence could enable medical breakthroughs and much longer human lives.
- His roughly 1,400-year estimate assumes mortality remains near youthful levels throughout life and is a hypothetical average.
- The former Oxford professor’s argument concerns future possibilities and the trade-offs around AI development, rather than a demonstrated anti-aging treatment.
AI could help humans live for 1,200 to 1,400 years if it enables medicine to overcome aging, philosopher Nick Bostrom argues. The striking figure comes with an equally large assumption: people would have to retain the low risk of death associated with healthy young adulthood throughout their lives.
Business Insider reported Bostrom’s remarks from a conversation on the a16z Show. His argument concerns a future in which superintelligent AI is developed safely and produces major biomedical breakthroughs. It is a scenario about what advanced technology might make possible, rather than a newly demonstrated treatment.
Bostrom is a former Oxford professor who founded the university’s Future of Humanity Institute. His official biography lists him as a philosopher at the Macrostrategy Research Initiative and dates his Oxford role to 2005 through 2024.
Where the 1,400-Year Figure Comes From
In his 2026 working paper, Optimal Timing for Superintelligence, Bostrom models a world in which rejuvenation medicine keeps mortality near the level of healthy people in their early 20s in developed countries. Using an illustrative annual death risk of about 0.07% gives an average remaining lifespan of roughly 1,400 years.
That average would not mean everyone reaches the same age, or that death disappears. Accidents and other hazards would remain. Bostrom considers even longer lives conceivable if advanced AI also helped reduce those risks.
The paper assumes the medical transformation in order to explore its consequences. It does not demonstrate how to deliver it or establish when it could happen.
Why Longevity Changes the AI Safety Debate
In the conversation hosted by Andreessen Horowitz, Bostrom weighs potential medical gains against the dangers of losing control of powerful AI. Delaying development might allow more safety work, but it could also postpone treatments for people who continue to die from disease and aging.
That reasoning supports his interest in controlling the pace of frontier development and preserving the ability to slow down. The value of a delay depends on how much safety it buys and which benefits it postpones; his position is more qualified than a call to develop AI at any cost.
What Aging Research Still Has to Prove
A National Institute on Aging workshop identified AI, organoids and large human datasets as promising ways to improve aging research. Its summary also stressed the difficulty of translating findings from experimental systems into human benefits and cautioned against reducing aging to a single numerical measure.
The enthusiasm extends beyond philosophy. OpenAI president Greg Brockman has also argued that AI could transform medicine and the prospects for longevity. Such forecasts describe the scale of the ambition. Establishing that an intervention safely extends healthy human life requires evidence from people.
Disclaimer: AIstify is an independent media brand owned and operated by NuvexMedia LLC, publishing news, research, and insights on artificial intelligence, emerging technologies, automation, and related industries. NuvexMedia LLC invests in and collaborates with companies across the AI, technology, software, and digital innovation sectors. These relationships do not influence AIstify’s editorial coverage, and the publication maintains full editorial independence to provide accurate, timely, and objective information. © 2026 NuvexMedia LLC. All rights reserved. This content is for informational purposes only and should not be considered legal, tax, investment, financial, or other professional advice.